Brought to you by 
Solvay buys Unimed for $108.7mm in cash
01 Feb 2000
Executive Summary
Solvay Pharmaceuticals (women's health, gastroenterology, cardiology, and mental health) is buying Unimed (endocrinology, urology, and infectious diseases) for about $108.7mm, paying $12 in cash for each Unimed common share, about a (pr)10% premium to its 10-day pre-announcement trading price.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Solvay buys Unimed for $108.7mm in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice